Glythera - PermaLink™
Manufactured by Glythera
Glythera’s PermaLink™ technology is a controlled, stable conjugation platform composed of a portfolio of linker...
Glythera’s PermaLink™ technology is a controlled, stable conjugation platform composed of a portfolio of linker designs. PermaLink™ can be employed for the selective and stable functionalization and conjugation of various cargos to proteins and peptides.
Due to its increased stability and selectivity, PermaLink™ offers significant benefits in the development of next generation biologics:
Antibody Drug Conjugates
(ADCs) are highly potent biologics composed of a tumour specific antibody linked via a linker to a cytotoxic drug. One of the crucial requirements for improving the therapeutic window of ADCs is specific and stable attachment of a potent cytotoxic agent to the antibody via the linker. Benefits of using PermaLink™:
Highly specific for the sulfhydryl groups of cysteine residues which are a primary site for cytotoxic drug attachment in many ADCs currently in clinical development
Enhanced stability provided by a stable thioether bond which is resistant to biological and chemical degradation
Compatible with a diverse range of cytotoxic payloads due to the ability to be tailored to generate both “non-cleavable” and “cleavable” linkers for efficient release of active drug following antigen-mediated internalization
Due to its increased stability and selectivity, PermaLink™ offers significant benefits in the development of next generation biologics:
Antibody Drug Conjugates
(ADCs) are highly potent biologics composed of a tumour specific antibody linked via a linker to a cytotoxic drug. One of the crucial requirements for improving the therapeutic window of ADCs is specific and stable attachment of a potent cytotoxic agent to the antibody via the linker. Benefits of using PermaLink™:
Active Questions & AnswersAsk a Question
There are no current Discussions
Antibodies Service ProvidersView All (3)
Documents & Manuals
There are no Documents or Manuals available.
Features of PermaLink™
- Comparative model system * Controlled Drug to Antibody Ratio (DAR) * Improved linker stability compared to maleimide based technologies * Comparable in vitro activity * Low immunogenic potential
General Specifications
There are no General Specifications available.